* Vertex adds black box warning to Incivek label
* Warning tied to reports of serious, fatal skin reactions
* Vertex says safety of patients its first priority
Dec 19 Vertex Pharmaceuticals Inc warned on Wednesday its hepatitis C drug Incivek, which is used in conjunction with two other products, can cause serious, potentially fatal skin reactions.
Skin rashes were already a known side effect of Incivek, but an analysis of data since the drug was approved in the United States in 2011 has revealed a number of cases in which the reaction was more severe than those seen in clinical trials of the drug. Some were fatal.
The findings have led Cambridge, Massachusetts-based Vertex to place an enhanced warning, surrounded by a black box, on the drug's prescribing label. Black box warnings are the most serious available.
Incivek is Vertex's flagship product. It is approved to treat hepatitis C, a viral infection that affects the liver, in combination with interferon and ribavirin.
The company said the fatal cases of skin reactions occurred in patients who continued to receive Incivek combination treatment after a serious skin reaction was identified.
GM says ISS advises against Greenlight share plan, board nominees
May 27 General Motors Co said on Saturday that proxy advisory firm Institutional Shareholder Services has recommended that shareholders vote against a slate of directors proposed by hedge fund Greenlight Capital and reject the hedge fund's plan to divide GM shares into two classes.
Fairfax Financial to sell 12.2 pct of Indian insurer ICICI Lombard
MUMBAI, May 27 Canada's Fairfax Financial Holdings plans to sell a 12.2 percent stake in its Indian joint venture insurer ICICI Lombard in a deal that will value the company at 203 billion rupees ($3.15 billion), the Indian company said on Saturday.